SeekingAlpha · Aug 8, 2026
Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript
Merck KGaA (MKKGY) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsFlorian Schraeder - Head of Investor RelationsKai Beckmann - CEO...
OTC · MKKGY
Merck KGaA
Healthcare · Drug Manufacturers - Specialty & Generic
$31.55
Down-$0.73 (-2.26%)
Updated Aug 14, 2026, 4:56 PM
SID Score
8.1/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 61.14B
- P/E ratio
- 17.39
- Dividend yield
- 1.58%
- 52-week range
- $23.73 – $34.19
- Volume
- 21.73K
- Avg. volume
- 155.75K
Price performance
MKKGY price history
1M range · 17 trading sessions · Daily adjusted prices
MKKGY closed at $33.38 after 17 trading sessions, up 5.60% for the selected period.
- Last close
- $33.38
- Period change
- +5.60%
- Period low
- $30.66
- Period high
- $33.83
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 7, 2026 | $33.457 | $33.62 | $33.065 | $33.38 | 21.73K |
| Aug 6, 2026 | $33.22 | $33.84 | $33.07 | $33.79 | 149.4K |
| Aug 5, 2026 | $33.45 | $33.77 | $33.37 | $33.66 | 27.46K |
| Aug 4, 2026 | $33.48 | $34.01 | $33.41 | $33.83 | 33.93K |
| Aug 3, 2026 | $33.16 | $33.29 | $32.85 | $32.91 | 28.23K |
| Jul 31, 2026 | $33.16 | $33.22 | $32.86 | $33.17 | 25.28K |
| Jul 30, 2026 | $32.96 | $33.18 | $32.904 | $33.15 | 27.65K |
| Jul 29, 2026 | $32.926 | $33.35 | $32.75 | $32.91 | 29.91K |
| Jul 28, 2026 | $32.60 | $33.022 | $32.59 | $32.96 | 28.25K |
| Jul 27, 2026 | $32.15 | $32.33 | $32.06 | $32.265 | 39.24K |
| Jul 24, 2026 | $31.96 | $31.9823 | $31.635 | $31.635 | 42.86K |
| Jul 23, 2026 | $31.42 | $31.88 | $31.42 | $31.70 | 35.02K |
| Jul 22, 2026 | $31.511 | $31.63 | $31.23 | $31.25 | 55.38K |
| Jul 21, 2026 | $29.77 | $30.86 | $29.77 | $30.76 | 35.33K |
| Jul 20, 2026 | $31.08 | $31.08 | $30.66 | $30.66 | 31.84K |
| Jul 17, 2026 | $31.17 | $31.37 | $30.8385 | $31.15 | 39.93K |
| Jul 16, 2026 | $31.81 | $31.81 | $31.36 | $31.61 | 47.95K |
Latest MKKGY news
The latest Smart Investors Daily articles mentioning MKKGY.
Stock researchCompany · Overview
MKKGY research
Overview
Company profile and research snapshot.
Company profile
MERCK KGAA SPNS/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $53.96
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 12, 2026 | DAY BY DAY | Buy | — |
| Jul 12, 2026 | LANDESBANK BADEN-WUERTTEMBERG | Buy | — |
| Jul 8, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jun 25, 2026 | ODDO BHF | Buy | — |
| Jun 25, 2026 | EQUITA SIM | Hold | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 7, 2026
Merck KGaA 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Merck KGaA in conjunction with their 2026 Q2 earnings call.
Yahoo · Jun 26, 2026
Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?
Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Yahoo · Jun 26, 2026
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
